Evidence map›Paper›PMID 26928401›Full record

ArticleJournal of pharmaceutical sciences2016

Transdermal Delivery of Iron Using Soluble Microneedles: Dermal Kinetics and Safety.

Naresh Modepalli, H Nanjappa Shivakumar, Maeliosa T C McCrudden, Ryan F Donnelly, Ajay Banga, S Narasimha Murthy

Open access · greenAbstract read
In one paragraph

Article in Journal of pharmaceutical sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Refining Treatment Strategies for Iron Deficient Athletes.Sports medicine (Auckland, N.Z.) · 2020
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Naresh ModepalliThe University of Mississippi School of Pharmacy, Mississippi 38677.
H Nanjappa ShivakumarInstitute for Drug Delivery and Biomedical Research, Bangalore, India; KLE's University College of Pharmacy, Bangalore, India.
Maeliosa T C McCruddenSchool of Pharmacy, Queen's University Belfast, Belfast, UK.
Ryan F DonnellySchool of Pharmacy, Queen's University Belfast, Belfast, UK.
Ajay BangaCollege of Pharmacy, Mercer University, Atlanta, Georgia 30341.
S Narasimha MurthyThe University of Mississippi School of Pharmacy, Mississippi 38677; Institute for Drug Delivery and Biomedical Research, Bangalore, India. Electronic address: murthy@olemiss.edu.
Queen's University Belfast · GBUniversity of Mississippi · USKLE University · INMercer University Health Sciences Center · US

Funding

TRANSDERMAL DELIVERY OF IRONR03HD061531 · NICHD · UNIVERSITY OF MISSISSIPPI · PI MURTHY, SATHYANARAYANA N · 2010 to 2011
$136k
NICHD NIH HHS HD061531-01NICHD NIH HHS R03 HD061531
6 · The paper itself

Abstract

Currently, the iron compounds are administered via oral and parenteral routes in patients of all ages, to treat iron deficiency. Despite continued efforts to supplement iron via these conventional routes, iron deficiency still remains the most prevalent nutritional disorder all over the world. Transdermal replenishment of iron is a novel, potential approach of iron replenishment. Ferric pyrophosphate (FPP) was found to be a suitable source of iron for transdermal replenishment. The safety of FPP was assessed in this project by challenging the dermal fibroblast cells with high concentration of FPP. The cell viability assay and reactive oxygen species assay were performed. The soluble microneedle array was developed, incorporated with FPP and the kinetics of free iron in the skin; extracellular fluid following dermal administration of microneedle array was investigated in hairless rats. From the cell based assays, FPP was selected as one of the potential iron sources for transdermal delivery. The microneedles were found to dissolve in the skin fluid within 3 hours of administration. The FPP concentration in the dermal extracellular fluid declined after complete dissolution of the microneedle array. Overall, the studies demonstrated the safety of FPP for dermal delivery and the feasibility of soluble microneedle approach for transdermal iron replenishment therapy.

Indexed as

Administration, CutaneousAnimalsCell SurvivalDiphosphatesDrug Delivery SystemsFibroblastsHumansIronKineticsMicroinjectionsNeedlesRatsRats, HairlessReactive Oxygen SpeciesSafetySkinDiphosphatesferric pyrophosphateIronReactive Oxygen Speciescell lineskineticsmicroarraysmicrodialysisreactive oxygen speciesskintransdermal drug delivery

Identifiers

PMID26928401
PMCPMC4773914
OpenAlexW2284379128

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.